FindTrial
Sign In

NTI164

DRUG6 trials

Sponsors

Fenix Innovation Group

Conditions

AutismAutism DisorderAutism Spectrum DisorderHealthyHealthy VolunteerPANS Pediatric Acute-Onset Neuropsychiatric SyndromeRETT Syndrome With Proven MECP2 MutationRett Syndrome

Phase 1

Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS)
CompletedNCT06621888
Fenix Innovation GroupPANS Pediatric Acute-Onset Neuropsychiatric Syndrome
Start: 2023-06-02End: 2025-12-01Updated: 2026-09-09
Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT)
CompletedNCT06621043
Fenix Innovation GroupRett Syndrome
Start: 2023-09-20End: 2025-12-01Updated: 2026-09-09
NTI164 Human PK Study
CompletedNCT06713447
Fenix Innovation GroupHealthy, Healthy Volunteer
Start: 2024-02-01End: 2025-06-01Updated: 2026-09-09

Phase 2

Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder
CompletedNCT05626959
Fenix Innovation GroupAutism Spectrum Disorder
Start: 2022-11-30End: 2026-05-30Updated: 2026-09-10
Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
Not yet recruitingNCT07257978
Fenix Innovation GroupRett Syndrome, RETT Syndrome With Proven MECP2 Mutation
Start: 2027-07-01End: 2028-10-01Target: 40Updated: 2026-09-09

Phase 3

NTI164 in Autism Spectrum Disorder
Not yet recruitingNCT07257939
Fenix Innovation GroupAutism, Autism Disorder, Autism Spectrum Disorder
Start: 2026-09-30End: 2030-07-01Target: 98Updated: 2026-09-08